Kodiak Sciences Inc.
2631 Hanover Street
64 articles with Kodiak Sciences Inc.
Kodiak Sciences Announces Completion of Enrollment in the Company's Phase 1 Safety and Tolerability Study in Patients with Retinal Disease
Kodiak Sciences Inc. today announced that enrollment of patients in the company's phase 1 safety and tolerability study has been completed. First patient in was dosed on July 12, 2018 and last patient in was dosed on August 13, 2018.
Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors
Kodiak Sciences Inc. announced the appointments of Bassil I. Dahiyat, Ph.D., Robert A. Profusek, J.D., and Richard S. Levy, M.D. to its Board of Directors.
Kodiak Sciences Inc. announced that presentations on its research will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, being held from April 29 - May 3 in Honolulu, Hawaii.
Kodiak Sciences Inc. announced the completion of a $33 million mezzanine private financing of convertible notes.